Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Director Luke Evnin reported selling shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) common stock over three days, with the transactions totaling approximately $61,787. The sales occurred between ...
Horror has a plethora of subgenres, from slashers and zombies, to ghosts and vampires, and many more. An underappreciated subgenre is the werewolf film. Although there were classics like The Wolfman ...
Werewolf Therapeutics, Inc. (HOWL) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HOWL's 50-day simple moving average ...
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) is anticipated to issue its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce ...
Werewolf Therapeutics (NASDAQ:HOWL) just reported results for the second quarter of 2024. Werewolf Therapeutics reported earnings per share of -43 cents. This was below the analyst estimate for EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results